Patents Assigned to Janssen Biotech, Inc.
  • BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
    Publication number: 20230270786
    Abstract: Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.
    Type: Application
    Filed: February 27, 2023
    Publication date: August 31, 2023
    Applicants: JANSSEN BIOTECH, INC., NANJING LEGEND BIOTECH CO., LTD., LEGEND BIOTECH USA INC.
    Inventors: Xiaohu FAN, Jordan SCHECTER, Lida PACAUD, Michael HIRSCHMANN
  • Neutralizing human anti-CD27 antibodies
    Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Subcutaneous formulations of anti-CD38 antibodies and their uses
    Patent number: 11732051
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: August 22, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
    Patent number: 11713355
    Abstract: The present invention relates to combination therapies with anti-CD38 antibodies.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: August 1, 2023
    Assignee: Janssen Biotech, Inc.
    Inventor: Parul Doshi
  • Differentiation of human embryonic stem cells
    Patent number: 11708562
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: July 25, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Alireza Rezania, Jean Xu
  • Subcutaneous formulations of anti-CD38 antibodies and their uses
    Patent number: 11708419
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: July 25, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Subcutaneous formulations of anti-CD38 antibodies and their uses
    Patent number: 11708420
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: July 25, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Cysteine engineered fibronectin type III domain binding molecules
    Patent number: 11702475
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: July 18, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD40 ANTIBODY
    Publication number: 20230174658
    Abstract: Methods for clinically proven safe administration of an anti-CD40 antibody by intravenous administration are provided. Also provided are methods for clinically proven safe treatment of advanced solid tumors by intravenous administration of an anti-CD40 antibody.
    Type: Application
    Filed: May 27, 2020
    Publication date: June 8, 2023
    Applicant: JANSSEN BIOTECH, INC.
    Inventor: Michael STREIT
  • Materials and methods for modulating t cell mediated immunity
    Patent number: 11667712
    Abstract: Anti-TRGV9 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: June 6, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh
  • METHODS FOR MAKING INSULIN IN VIVO
    Publication number: 20230151332
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 18, 2023
    Applicant: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES
    Publication number: 20230138852
    Abstract: Provided herein are high-pressure liquid chromatography (HPLC) methods for detecting multi-specific molecule formation after a multi-specific molecule manufacturing or development process. The HPLC methods provide fast, quantitative, real-time processing of multi-specific molecule formation.
    Type: Application
    Filed: April 15, 2021
    Publication date: May 4, 2023
    Applicant: Janssen Biotech, Inc.
    Inventors: James Martosella, Jessika S. Feliciano-Cardona, Gulnur Elove
  • Antibody binding to a linker peptide
    Patent number: 11639396
    Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: May 2, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Sanjaya Singh, Rajkumar Ganesan, Jun Chen, Iqbal S. Grewal
  • COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES
    Publication number: 20230130600
    Abstract: The present invention relates to combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies.
    Type: Application
    Filed: August 3, 2022
    Publication date: April 27, 2023
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Sheri MOORES, Smruthi VIJAYARAGHAVAN
  • Palm activated drug delivery device
    Patent number: 11633546
    Abstract: Disclosed is a device for the parenteral delivery of a medication, such as a drug. The device includes upper and lower housings in which the upper housing is configured to move relative to the lower housing as a result of application of an external force to permit the user of the device to control the rate at which the drug is administered.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 25, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Lorin P. Olson, Peter Krulevitch, James Glencross, Jingli Wang, Nicholas Foley, Mingqi Zhao
  • Control of trace metals during production of anti-CD38 antibodies
    Patent number: 11634499
    Abstract: The disclosure relates to methods to control trace metals during production of anti-CD38 antibodies, drug substances and drug products generated using the methods, and uses of the generated drug substances and drug products.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: April 25, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Nicole Larmore, Balasubramanian Ramanathan, Richard Yeager
  • Methods of treating high risk multiple myeloma
    Patent number: 11618787
    Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: April 4, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Tahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
  • SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20230086795
    Abstract: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Hyunjoo LEE, Su Bin CHOI, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell Robertson, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
  • 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20230085912
    Abstract: Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
  • 6-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20230090406
    Abstract: Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 23, 2023
    Applicants: YUHAN CORPORATION, JANSSEN BIOTECH, INC.
    Inventors: Hyunjoo LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM